Moderna

Moderna's moat score of 18/100 reflects the significant challenges associated with sustaining a competitive advantage in the biotechnology sector, particularly following a unique market event like the COVID-19 pandemic.

The company's reliance on its mRNA platform, while innovative, has proven susceptible to market normalization and increased competition, as evidenced by the dramatic 3-year revenue CAGR of -53.4%.

This suggests that the strong market position enjoyed during the pandemic was more a function of urgent, widespread demand than a deeply entrenched, enduring competitive barrier.

While patent protection for specific mRNA technologies provides some temporary exclusivity, the rapid development cycles and evolving nature of infectious diseases mean that sustained leadership requires constant innovation and successful pipeline diversification.

The current score indicates that Moderna is struggling to convert its initial success into a durable, multi-product moat, necessitating a clear demonstration of new blockbuster drugs to regain investor confidence in its long-term competitive standing beyond its initial vaccine success.